Functional Signaling Biases in G Protein-Coupled Receptors: Game Theory and Receptor Dynamics

被引:36
作者
Maudsley, S. [1 ]
Patel, S. A. [2 ]
Park, S. -S.
Luttrell, L. M. [3 ]
Martin, B. [4 ]
机构
[1] NIA, Receptor Pharmacol Unit, NIH, Biomed Res Ctr, Baltimore, MD 21224 USA
[2] Univ Maryland Baltimore Cty, Cognit Robot & Learning Lab, Dept Comp Sci & Elect Engn, Baltimore, MD 21228 USA
[3] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA
[4] NIA, Metab Unit, NIH, Baltimore, MD 21224 USA
基金
美国国家卫生研究院;
关键词
G protein-coupled receptor; biased agonist; signaling; drug design; aging; allostasis; DYSTROPHIN-ASSOCIATED PROTEIN; EXCHANGER REGULATORY FACTOR; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; HEART-FAILURE; AGONIST TRAFFICKING; ANTAGONISTS PROMOTE; PARATHYROID-HORMONE; ACTIVATION; ARRESTIN;
D O I
10.2174/138955712800959071
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pharmacotherapeutic targeting of G protein-coupled receptors (GPCRs) is perhaps the most important field of drug design, as agents designed to control these receptors constitute more than half of the pharmacopeia. Initially GPCRs were considered to be unitary entities, possessing all of their potential functionality in their characteristic heptahelical core. Early models of the functional activity of GPCRs considered them to possess just a simple 'on' or 'off' status. Recent research however has allowed us to realize that GPCR functionality is dependent upon many other proteins outside of the heptahelical core, on the site of GPCR expression in a tissue or a microdomain in a cell, and, most importantly, on the formation of differential 'active' states preferentially coupled to specific signal transduction structures. The recognition of such signaling diversity has facilitated the ability to appreciate and identify ligands for GPCRs that demonstrate a bias towards one signaling form of a receptor to another. However while potentially increasing our ability for selective signal targeting, our approach to understanding the physiological ramifications of systemic signaling manipulation is underdeveloped. This explosion in the complexity of GPCR signaling is now becoming familiar territory to receptor biologists, yet the application of this knowledge to drug design is relatively limited. This review will attempt to outline potential pitfalls and unseen benefits of using signaling bias in therapeutic design as well as highlighting new applications such as Game Theory for uncovering new therapeutic applications for biased agonists.
引用
收藏
页码:831 / 840
页数:10
相关论文
共 77 条
[1]   2 FORMS OF MOUSE SYNTROPHIN, A 58-KD DYSTROPHIN-ASSOCIATED PROTEIN, DIFFER IN PRIMARY STRUCTURE AND TISSUE DISTRIBUTION [J].
ADAMS, ME ;
BUTLER, MH ;
DWYER, TM ;
PETERS, MF ;
MURNANE, AA ;
FROEHNER, SC .
NEURON, 1993, 11 (03) :531-540
[2]   Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2α-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts [J].
Ahmed, I ;
Gesty-Palmer, D ;
Drezner, MK ;
Luttrell, LM .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (08) :1607-1621
[3]   CLONING OF HUMAN BASIC A1, A DISTINCT 59-KDA DYSTROPHIN-ASSOCIATED PROTEIN ENCODED ON CHROMOSOME 8Q23-24 [J].
AHN, AH ;
YOSHIDA, M ;
ANDERSON, MS ;
FEENER, CA ;
SELIG, S ;
HAGIWARA, Y ;
OZAWA, E ;
KUNKEL, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4446-4450
[4]   SYNTROPHIN BINDS TO AN ALTERNATIVELY SPLICED EXON OF DYSTROPHIN [J].
AHN, AH ;
KUNKEL, LM .
JOURNAL OF CELL BIOLOGY, 1995, 128 (03) :363-371
[5]  
Andresen Bradley T., 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P90
[6]   An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior [J].
Beaulieu, JM ;
Sotnikova, TD ;
Marion, S ;
Lefkowitz, RJ ;
Gainetdinov, RR ;
Caron, MG .
CELL, 2005, 122 (02) :261-273
[7]   Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists [J].
Berg, KA ;
Maayani, S ;
Goldfarb, J ;
Clarke, WP .
ADVANCES IN SEROTONIN RECEPTOR RESEARCH: MOLECULAR BIOLOGY, SIGNAL TRANSDUCTION, AND THERAPEUTICS, 1998, 861 :104-110
[8]   Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus [J].
Berg, KA ;
Maayani, S ;
Goldfarb, J ;
Scaramellini, C ;
Leff, P ;
Clarke, WP .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :94-104
[9]  
Bonhaus DW, 1998, J PHARMACOL EXP THER, V287, P884
[10]  
CARTAUD A, 1993, J BIOL CHEM, V268, P13019